Candidate: Vaccine to protect against SARS-CoV-2

Category: VAX

Type: Not specified

Status: USask on March 13 said VIDO-InterVac researchers had successfully grown SARS-Cov-2 in a cell culture, and were testing the vaccine candidate in animals. VIDO-InterVac said it was collaborating with several labs in and outside Canada, including the National Microbiology Laboratory in Winnipeg.

Volker Gerdts, DVM, director and CEO of VIDO-InterVac, said in a statement that resarchers hoped to have an indication by early April whether the vaccine generated at VIDO-InterVac can successfully protecting against SARS-coV-2. He anticipated another six months of testing, development and manufacturing would be needed before the vaccine would be ready for clinical testing.

VIDO-InterVac said it is working to build a pilot-scale manufacturing facility within its Level 3 containment facility. VIDO-InterVac received funding to start Phase 1 of the facility, but will need another C$10 million ($7 million) to fully establish the manufacturing facility to industry standards, Gerdts said.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

Previous articleMerck KGaA
Next articleImmunic – IMU-838